Development and Evaluation of a Korean Version of a Thyroid-Specific Quality-of-Life Questionnaire Scale in Thyroid Cancer Patients

Ryu, Chang Hwan; Park, Boram; Ryu, Junsun; Ryu, Youn Mi; Jo, Seong Ae; Lee, You Jin; Lee, Eunkyung; Hwangbo, Yul; Joo, Jungnam; Jung, Yuh‐Seog

doi:10.4143/crt.2017.012

Cited by 26 publications

(26 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood pressure and pulse rate were measured at the heart level in the seated position using a standardized cuff, and the measurements were performed after 5 minutes of rest and repeated after another 5 minutes of rest. The Korean version of a thyroid-specific QOL questionnaire has been developed specifically for patients with thyroid cancer [ 16 ]. Medical histories and anthropometric measures were evaluated at the enrollment and every follow-up visit.…”

Section: Methodsmentioning

confidence: 99%

Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundThe ongoing Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) aims to observe the natural course of papillary thyroid microcarcinoma (PTMC), develop a protocol for active surveillance (AS), and compare the long-term prognosis, quality of life, and medical costs between the AS and immediate surgery groups.MethodsThis multicenter prospective cohort study of PTMC started in June 2016. The inclusion criteria were suspicious of malignancy or malignancy based on fine needle aspiration or core needle biopsy, age of ≥18 years, and a maximum diameter of ≤1 cm. If there was no major organ involvement, no lymph node/distant metastasis, and no variants with poor prognosis, the patients were explained of the pros and cons of immediate surgery and AS before selecting AS or immediate surgery. Follow-up visits (physical examination, ultrasonography, thyroid function, and questionnaires) are scheduled every 6 months during the first 2 years, and then every 1 year thereafter. Progression was defined as a maximum diameter increase of ≥3, ≥2 mm in two dimensions, suspected organ involvement, or lymph node/distant metastasis.ResultsAmong 439 enrolled patients, 290 patients (66.1%) chose AS and 149 patients (33.9%) chose immediate surgery. The median follow-up was 6.7 months (range, 0.2 to 11.9). The immediate surgery group had a larger maximum tumor diameter, compared to the AS group (7.1±1.9 mm vs. 6.6±2.0 mm, respectively; P=0.014).ConclusionThe results will be useful for developing an appropriate PTMC treatment policy based on its natural course and risk factors for progression.

show abstract

Section: Methodsmentioning

confidence: 99%

Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been reported that an obstacle to evaluating illness perception in patients with thyroid cancer is the lack of specific questionnaires [15], such as those used for thyroid-associated ophthalmopathy [20] and disease-specific morbidity [7]. In pediatric [21], adolescent [22], and adult DTC patients [1, 5-9, 12, 16], QoL has been evaluated by means of several inventories. Massolt et al [16] first evaluated QoL in a group of 143 adult DTC patients by means of the ThyPRO questionnaire.…”

Section: Discussionmentioning

confidence: 99%

“…Other authors [8, 26] found no association between QoL and TSH concentration. Recently, Ryu et al [12] used the Korean translation of the thyroid-specific QoL scale (KT-QoL) to analyze QoL in a cohort of subjects before and 12 months after thyroid surgery for DTC. Their analysis showed that QoL decreased after surgery, and that QoL impairment was less severe when lobectomy was the surgical choice [12].…”

Section: Discussionmentioning

confidence: 99%

“…In the same period, a literature review [11], in which 16 papers regarding QoL in DTC patients were selected, revealed that several factors (surgery, radioiodine therapy, thyroid hormone withdrawal instead of rhTSH administration, access to behavioral help, patient-physician relationship) had both a physical and psychological impact on patients. Finally, Ryu et al [12] also analyzed the dimension of spiritual well-being, which is not generally explored by other questionnaires, and found that it improved after surgery in patients with DTC of all tumor stages. In 2011, we published a case-controlled longitudinal study on QoL in 128 DTC patients followed up for 5 years, to whom the self-rated Kellner Symptom Questionnaire was administered yearly, in association with a semi-structured psychiatric interview and four other inventories; 219 patients who had undergone surgery for benign thyroid pathology served as a control group [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Quality of Life in Patients with Differentiated Thyroid Cancer by Means of the Thyroid-Specific Patient-Reported Outcome Questionnaire: A 5-Year Longitudinal Study

Giusti¹,

Gay²,

Conte³

et al. 2019

Eur Thyroid J

View full text Add to dashboard Cite

Background: Patients with malignancy suffer impairment of their quality of life (QoL). QoL has been evaluated in thyroid cancer patients. Since 2010, a new inventory, the thyroidspecific patient-reported outcome (ThyPRO) measure for benign thyroid disorders, has been available. Aim: This study evaluated QoL longitudinally in patients with a history of differentiated thyroid cancer (DTC) by means of the ThyPRO questionnaire. Methods: From 2012 to 2016, QoL was evaluated yearly in 123 adult DTC patients by means of ThyPRO. The ThyPRO questionnaire consists of 13 scales on which higher scores represent greater impact on QoL in areas affected by thyroid pathology. Disease-specific morbidity due to possible inadequate L-T4 treatment was evaluated by means of the Billewicz scale (BS). The same examinations were conducted in 192 control subjects who had undergone surgery for benign thyroid pathology. Results: DTC and control subjects had similar scores on all but one scale; scores on the hyperthyroid symptoms scale were significantly higher in DTC patients than in controls. Over the 5 years, scores did not change significantly in the DTC group. Overall, QoL and BS scores showed a slight, but not significant, improvement during the study period in DTC patients. BMI impacted on several ThyPRO scales. No significant differences between genders were noted in DTC. Conclusions: The ThyPRO questionnaire indicates that illness perception is similar after thyroidectomy for malign and benign pathology. Only a marginal improvement in QoL was noted in DTC subjects over the 5-year study period. In both groups, females showed a greater perception of illness than males.

show abstract

“…The secondary endpoints of this trial include recurrence-free survival, QOL, and disease-specific survival. QOL will be assessed by the validated Korean version of the thyroid-specific QOL questionnaire (KT-QoL) [6,7]. The QOL questionnaire evaluates four domains: physical, psychological, social and spiritual aspects.…”

Section: Secondary Outcomesmentioning

confidence: 99%

A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol

Lee

Park

et al. 2020

Endocrinol Metab

Self Cite

View full text Add to dashboard Cite

Background: Radioactive iodine (RAI) remnant ablation is recommended in patients with papillary thyroid cancer (PTC) and extrathyroidal extension or central lymph node metastasis. However, there exists little evidence about the necessity of remnant ablation in PTC patients with low-to intermediate-risk, those have been increasing in recent decades. Methods: This multicenter, prospective, non-randomized, parallel group clinical trial will enroll 310 eligible patients with low-to intermediate-risk of thyroid cancer. Inclusion criteria are patients who recently underwent total thyroidectomy for PTC with 3 or less tumors of size 1≤ to ≤2 cm with no microscopic extension and N0/x, or size ≤2 cm with microscopic extension and/or N1a (number of lymph node ≤3, size of tumor foci ≤0.2 cm, and lymph node ratio <0.4). Patients choose to undergo RAI ablation (131 I, dose 1.1 GBq) or diagnostic whole-body scan (DxWBS) (131 I or 123 I, dose 0.074 to 0.222 GBq), followed by subsequent measurement of stimulated thyroglobulin (sTg) within 1 year. Survey for quality of life (QOL) will be performed at baseline and at 1 year after follow-up. The total enrollment period is 5 years, and patients will be followed up for 1 year. The primary endpoint is the non-inferiority of surgery alone to surgery with ablation in terms of biochemical remission (BCR) rate (sTg ≤2 ng/mL) without evidence of structural recurrence. The secondary endpoint was the difference of QOL. Conclusion: This study will evaluate whether surgery alone achieves similar BCR and improved QOL compared to RAI ablation in patients with low-to intermediate-risk PTC within 1 year.

show abstract

Development and Evaluation of a Korean Version of a Thyroid-Specific Quality-of-Life Questionnaire Scale in Thyroid Cancer Patients

Cited by 26 publications

References 19 publications

Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)

Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)

Evaluation of Quality of Life in Patients with Differentiated Thyroid Cancer by Means of the Thyroid-Specific Patient-Reported Outcome Questionnaire: A 5-Year Longitudinal Study

A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol

Contact Info

Product

Resources

About